Swinging the SWI/SNF complexes for cancer therapy

Area of Science:

• Epigenetics and Cancer Genomics
• Chromatin Biology
• Molecular Oncology

Background:

• SWI/SNF chromatin remodeling complexes are crucial epigenetic regulators.
• Alterations in SWI/SNF components are frequently observed in human cancers, contributing to tumorigenesis.
• Understanding the oncogenic roles of SWI/SNF complexes is vital for developing targeted therapies.

Purpose of the Study:

• To integrate large-scale cancer genomic data to understand tumorigenesis driven by SWI/SNF subunit alterations.
• To evaluate therapeutic strategies targeting vulnerabilities in SWI/SNF-mutant cancers.
• To provide an overview of current and emerging treatments for SWI/SNF-altered cancers.

Main Methods:

• Integration of large-scale cancer genomic datasets.
• Analysis of SWI/SNF complex subunit alterations across various cancer types.
• Review of preclinical and clinical data on therapeutic strategies.

Main Results:

• SWI/SNF alterations are common drivers of tumorigenesis through diverse mechanisms.
• Targeting residual SWI/SNF components and unique cellular dependencies shows promise.
• One drug targeting SWI/SNF vulnerabilities is approved, with others in clinical trials.

Conclusions:

• Aberrant SWI/SNF complexes represent a significant therapeutic target in oncology.
• Exploiting specific vulnerabilities in SWI/SNF-mutant cancers offers a promising avenue for treatment development.
• Continued research and clinical investigation are essential for advancing therapies for SWI/SNF-altered cancers.